SCHEMBL26615768

SCHEMBL26615768

COC(=O)c1c(C(F)(F)F)cnc(Cl)c1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.42
MAPT P10636 2/20 0.40
MRGPRX4 Q96LA9 2/20 0.36
MAPK1 P28482 1/20 0.35
CFTR P13569 2/20 0.35
PDGFRB P09619 1/20 0.34
KDR P35968 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90B1 P14625 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
LMNA P02545 1/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31368751 0.85 MAPT (0.41) NOTUMMAPTMRGPRX4MAPK1CFTR
SCHEMBL26616112 0.84 NOTUM (0.43) NOTUMMAPTMRGPRX4MAPK1CFTR
SCHEMBL30631449 0.84 NOTUM (0.43) NOTUMMAPTMRGPRX4MAPK1CFTR
SCHEMBL30562714 0.81 MAPT (0.41) NOTUMMAPTMRGPRX4MAPK1CFTR
SCHEMBL25388415 0.81 MAPT (0.41) NOTUMMAPTMRGPRX4MAPK1CFTR
SCHEMBL26608178 0.74 PIK3CD (0.36)
SCHEMBL30631544 0.74 PIK3CD (0.36)
SCHEMBL6381481 0.73 ATR (0.44) NOTUMMAPTMRGPRX4CFTRHSP90AA1
SCHEMBL18940406 0.73 NOTUM (0.48) NOTUMMAPTMRGPRX4MAPK1PDGFRB
SCHEMBL30631385 0.72 NOTUM (0.36) NOTUMMRGPRX4LMNAMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503439-B2 Heteroaryl compounds for the treatment of pain VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-23 US disclosed
EP-4511116-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-23 US disclosed
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-23 US disclosed
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-23 US disclosed
WO-2023205463-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205463-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 NOTUM 1871/4885MAPT 2089/4885MRGPRX4 416/4885
US-12503439-B2 Heteroaryl compounds for the treatment of pain TRPV1, SCN3A, KCNN3 NOTUM 1871/4885MAPT 2089/4885MRGPRX4 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.